Sex-based differences in cardiac resynchronization therapy and implantable cardioverter defibrillator therapies: effectiveness and use.
With the rapid advancements in heart failure device therapy, many physicians now use these devices in everyday clinical practice. However, questions remain regarding the clinical benefit of these therapies in different patient subgroups. Since the majority of patients enrolled in device trials are white men, extrapolating the data to specific patient subpopulations becomes important. Specifically, the question of clinical outcomes in women with implantable device therapy for prevention of sudden cardiac death and management of heart failure is an important clinical issue. In this article, we review the data on survival and clinical outcomes with heart failure device therapy (implantable cardioverter defibrillators [ICDs] and cardiac resynchronization therapy [CRT]) and analyze the results from clinical trials for any differences in outcomes based on gender. Even though women are a significantly under-represented population with regard to clinical investigation and utilization of heart failure devices, they still derive the same morbidity and mortality benefits compared to men. Specifically, ICD devices confer the same rates of sudden cardiac death prevention, and CRT devices improve CHF morbidity and mortality at rates comparable to those found in men. These results support equal use of ICDs and CRT in men and women.
Yarnoz
Michael J
MJ
Division of Cardiovascular Disease, University of South Florida, Tampa, Florida 33612, USA.
Curtis
Anne B
AB
D002303:Cardiac Output, Low / Q000628:therapy*; D002304:Cardiac Pacing, Artificial / Q000706:statistics & numerical data; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000706:statistics & numerical data; D004554:Electric Countershock / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D012727:Sex Characteristics; D017678:Sex Distribution; D016019:Survival Analysis; D016896:Treatment Outcome